Device Trial Radar · NCT07925580
Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jun 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- University of MiamiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gabrielle's Angel Foundation for Cancer Research
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this study is to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS) improves chemotherapy-induced peripheral neuropathy (CIPN) symptoms by assessing changes in daily symptom trajectories following treatment initiation. The study will also examine potential mechanisms of action through longitudinal assessment of inflammatory biomarkers, corticospinal excitability, and autonomic nervous system function.
Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Sparrow Link (taVNS)Device
Participants will self-administer transcutaneous auricular vagus nerve stimulation (taVNS) using the Sparrow Link portable stimulator and flexible ear electrodes for 1 hour daily for 14 days (total stimulation time: 14 hours).The treatment stimulation intensity can be increased up to 5mA, but this will be adjusted for each participant to ensure it is below the pain threshold.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Daily Chemotherapy-Induced Peripheral Neuropathy Symptom Severity Measured by Numeric Rating Scale (NRS)Time frame: Baseline (Days -14 to 0), Treatment period (Day 1-14)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christine E Lynn Rehabilitation Center
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.